Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: The BAT randomized controlled trial

JAMA

Volumn 309, Issue 12, 2013, Pages 1251-1259

  Altenburg, Josje ^a   De Graaff, Casper S ^a   Stienstra, Ymkje ^b   Sloos, Jacobus H ^a   Van Haren, Eric H J ^c   Koppers, Ralph J H ^d   Van Der Werf, Tjip S ^b   Boersma, Wim G ^a  

^a Location Alkmaar   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c Sittard Geleen Heerlen   (Netherlands)

^d MEDICAL CENTER LEEUWARDEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; C REACTIVE PROTEIN; PLACEBO; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER;

ABDOMINAL PAIN; ADULT; ARTICLE; BACTERIOLOGY; BRONCHIECTASIS; BRONCHOGRAPHY; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL DISEASE; HEADACHE; HEARING DISORDER; HEART PALPITATION; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTENTION TO TREAT ANALYSIS; LONG TERM CARE; LOWER RESPIRATORY TRACT INFECTION; LUNG FIBROSIS; LUNG FUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NETHERLANDS; NON-CYSTIC FIBROSIS BRONCHIECTASIS; PARALLEL DESIGN; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; RISK FACTOR; SCORING SYSTEM; SPUTUM ANALYSIS; SYMPTOMATOLOGY; AGED; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BLOOD; CONTROLLED CLINICAL TRIAL; INFLAMMATION; LUNG; LUNG FUNCTION TEST; MICROBIOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; RESPIRATORY TRACT INFECTION; SPUTUM;

ADULT; AGED; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; BRONCHIECTASIS; DOUBLE-BLIND METHOD; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INFLAMMATION; LUNG; MALE; MIDDLE AGED; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; RESPIRATORY TRACT INFECTIONS; SPUTUM;

MLCS; MLOWN;

EID: 84875524849     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.1937     Document Type: Article

References (36)

1. Cole PJ. Inflammation: a two-edged sword - the model of bronchiectasis. Eur J Respir Dis Suppl. 1986;147:6-15. (Pubitemid 16017382)
2. ten Hacken NH, Wijkstra PJ, Kerstjens HA. Treatment of bronchiectasis in adults. BMJ. 2007;335(7629):1089-1093. (Pubitemid 350206282)
3. Bilton D. Update on non-cystic fibrosis bronchiectasis. Curr Opin Pulm Med. 2008;14(6):595-599.
4. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP. Long-term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo-controlled trial. Thorax. 2006;61(10):895-902. (Pubitemid 44570311)
5. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long-term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet. 2002;360(9338):978-984. (Pubitemid 35284109)
6. Saiman L, Marshall BC, Mayer-Hamblett N, et al Macrolide Study Group. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290(13):1749-1756. (Pubitemid 37430625)
7. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax. 2002;57(3):212-216. (Pubitemid 34214405)
8. McCormack J, Bell S, Senini S, et al. Daily versus weekly azithromycin in cystic fibrosis patients. Eur Respir J. 2007;30(3):487-495. (Pubitemid 351182072)
9. Anwar GA, Bourke SC, Afolabi G, Middleton P, Ward C, Rutherford RM. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respir Med. 2008;102(10):1494-1496.
10. Cymbala AA, Edmonds LC, Bauer MA, et al. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med. 2005;4(2):117-122. (Pubitemid 40613959)
11. Davies G, Wilson R. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax. 2004;59(6):540-541. (Pubitemid 38797534)
12. Koh YY, Lee MH, Sun YH, Sung KW, Chae JH. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J. 1997;10(5):994-999. (Pubitemid 27201800)
13. Tsang KW, Ho PI, Chan KN, et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J. 1999;13(2):361-364. (Pubitemid 29086834)
14. Yalçin E, Kiper N, Ozçelik U, et al. Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J Clin Pharm Ther. 2006;31(1):49-55.
15. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):660-667.
16. Moher D, Hopewell S, Schulz KF, et al Consolidated Standards of Reporting Trials Group. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010;63(8):e1-e37.
17. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med. 2010;7(3):e1000251.
18. Miller MR, Hankinson J, Brusasco V, et al ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26(2):319-338. (Pubitemid 41079078)
19. Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med. 2010;181(9):975-982.
20. Daniels JM, Snijders D, de Graaff CS, Vlaspolder F, Jansen HM, Boersma WG. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181(2):150-157.
21. Jones PW. St. George's Respiratory Questionnaire: MCID. COPD. 2005;2(1):75-79.
22. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation: the St. George's Respiratory Questionnaire. Am Rev Respir Dis. 1992;145(6):1321-1327.
23. Wilson CB, Jones PW, O'Leary CJ, Cole PJ, Wilson R. Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med. 1997;156(2, pt 1):536-541. (Pubitemid 27351991)
24. Serisier DJ, Martin ML. Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respir Med. 2011;105(6):946-949.
25. Knottnerus JA, Bouter LM. The ethics of sample size: two-sided testing and one-sided thinking. J Clin Epidemiol. 2001;54(2):109-110. (Pubitemid 32112367)
26. Martínez-García MA, Perpiñá-Tordera M, Román-Sánchez P, Soler-Cataluña JJ. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest. 2005;128(2):739-745. (Pubitemid 41140504)
27. Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J. 2009;34(4):843-849.
28. Saiman L, Anstead M, Mayer-Hamblett N, et al; AZ0004 Azithromycin Study Group. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2010;303(17):1707-1715.
29. Albert RK, Connett J, Bailey WC, et al COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689-698.
30. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics - part 2: advantages and disadvantages of long-term, low-dose macrolide therapy. Respiration. 2011;81(1):75-87.
31. Hansen CR, Pressler T, Hoiby N, Johansen HK. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients. J Cyst Fibros. 2009;8(1):58-62.
32. Kasahara K, Kita E, Maeda K, et al. Macrolide resistance of Streptococcus pneumoniae isolated during long-term macrolide therapy: difference between erythromycin and clarithromycin. J Infect Chemother. 2005;11(2):112-114. (Pubitemid 40645887)
33. Tramper-Stranders GA, Wolfs TF, Fleer A, Kimpen JL, van der Ent CK. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J. 2007;26(1):8-12. (Pubitemid 46045744)
34. Phaff SJ, Tiddens HA, Verbrugh HA, Ott A. Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis. J Antimicrob Chemother. 2006;57(4):741-746.
35. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366(20):1881-1890.
36. Banerjee D, Khair OA, Honeybourne D. The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respir Med. 2005;99(2):208-215. (Pubitemid 40104276)